Search by Drug Name or NDC
NDC 59148-0032-90 Abilify MyCite 15 mg/1 Details
Abilify MyCite 15 mg/1
Abilify MyCite is a ORAL TABLET WITH SENSOR in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Otsuka America Pharmaceutical, Inc.. The primary component is ARIPIPRAZOLE.
MedlinePlus Drug Summary
Aripiprazole is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions) in adults and teenagers 13 years of age and older. It is also used alone or with other medications to treat episodes of mania or mixed episodes (symptoms of mania and depression that happen together) in adults, teenagers, and children 10 years of age and older with bipolar disorder (manic-depressive disorder; a disease that causes episodes of depression, episodes of mania, and other abnormal moods). Aripiprazole is also used with an antidepressant to treat depression when symptoms cannot be controlled by the antidepressant alone. Aripiprazole is also used to treat children 6 to 17 years of age who have autistic disorder (a developmental problem that causes difficulty communicating and interacting with others). Aripiprazole may help control irritable behavior such as aggression, temper tantrums, and frequent mood changes in these children. Aripiprazole is also used to treat children 6 to 18 years of age who have Tourette's disorder (a condition characterized by the need to perform repeated motions or to repeat sounds or words). Aripiprazole is in a class of medications called atypical antipsychotics. It works by changing the activity of certain natural substances in the brain.
Related Packages: 59148-0032-90Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Aripiprazole
Product Information
NDC | 59148-0032 |
---|---|
Product ID | 59148-032_e9560dde-6499-413d-abc5-9f4b5ed8504f |
Associated GPIs | 59250015000377 59250015000378 59250015000375 |
GCN Sequence Number | 082063 |
GCN Sequence Number Description | aripiprazole TABSENSTPD 15 MG ORAL |
HIC3 | H7X |
HIC3 Description | ANTIPSYCHOTICS, ATYP, D2 PARTIAL AGONIST/5HT MIXED |
GCN | 49363 |
HICL Sequence Number | 024551 |
HICL Sequence Number Description | ARIPIPRAZOLE |
Brand/Generic | Brand |
Proprietary Name | Abilify MyCite |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | ARIPIPRAZOLE |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | TABLET WITH SENSOR |
Route | ORAL |
Active Ingredient Strength | 15 |
Active Ingredient Units | mg/1 |
Substance Name | ARIPIPRAZOLE |
Labeler Name | Otsuka America Pharmaceutical, Inc. |
Pharmaceutical Class | Atypical Antipsychotic [EPC] |
DEA Schedule | n/a |
Marketing Category | NDA |
Application Number | NDA207202 |
Listing Certified Through | 2024-12-31 |
Package
NDC 59148-0032-90 (59148003290)
NDC Package Code | 59148-032-90 |
---|---|
Billing NDC | 59148003290 |
Package | 1 BOTTLE in 1 KIT (59148-032-90) / 7 TABLET WITH SENSOR in 1 BOTTLE (59148-032-07) |
Marketing Start Date | 2018-01-31 |
NDC Exclude Flag | N |
Pricing Information | N/A |